Bio4Dreams acquires stake in OaCP IE LTD and launches an incubation program to support its growth in European markets and access to the US and Arab markets.
Born out of a research project at the University of Bologna and based in Cork, Ireland, OaCP develops reagents for cancer diagnostics that make DNA testing faster and more efficient.
Its products are already used by hospitals, laboratories, and research centers in Italy and Europe.
The transaction involved a co-investment through SAFE and ongoing strategic support to accelerate market development and address the FDA regulatory process, continuing a collaboration that began in 2022 withinthe Bio4Dreams ecosystem.
"The incubator's investment and strategic support provide us with the resources and expertise we need to decisively tackle the FDA regulatory process and scale our presence in both the US and Arab markets."
Enrico Di Oto, CEO of OaCP
“We have been working closely with OaCP for years and are well aware of its value: a team that combines scientific rigor with entrepreneurial vision.”
Demetra Pelos, Bio4Dreams
👉 Read the full news article
